...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumori. >Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
【24h】

Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.

机译：通过生长抑素受体闪烁显像和免疫组化检测生长抑素受体亚型2和5：胃肠道胰腺神经内分泌肿瘤的诊断和治疗管理中的临床意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims and background. Somatostatin receptor scintigraphy (SRS) is the standard method for the detection of somatostatin receptors (SSTRs). It is commonly used in gastroenteropancreatic neuroendocrine tumor (GEP-NET) staging, and represents the criterion of choice for treatment with somatostatin (SST) analogs. Immunohistochemistry (IHC) was reported as a reliable method for the detection of SSTRs with theoretically superior sensitivity over SRS. Methods and study design. We retrospectively analyzed the sensitivity and specificity of IHC in the detection of SSTRs in a cohort of consecutive patients with GEP-NETs attending our Institute from 1997 to 2007. IHC analysis was restricted to SSTR2 and SSTR5, and the results were interpreted according to two different scoring systems. SRS was used as the gold standard. Results. Forty-four patients were enrolled; 24 (55%) had foregut carcinoids, 9 (20%) midgut carcinoids, 2 (5%) hindgut carcinoids, and 9 (20%) had GEP-NETs of unknown primary sites. A high concordance rate between IHC and SRS was shown, irrespective of the IHC scoring system applied (73% and 70%). The sensitivity of IHC was 89.3% and 78.6% and the specificity 43.8% and 50%, depending on the scoring system used. Conclusions. Although SSTR2 was shown to be expressed by IHC in up to 50% of tumors not visualized by SRS, SRS still remains the method of choice in the diagnostic and therapeutic management of GEP-NETs. More pathological and clinical data are needed to properly understand the clinical relevance of immunohistochemical detection of SSTR expression in the absence of tumor uptake at SRS.
机译：目的和背景。生长抑素受体闪烁显像术（SRS）是检测生长抑素受体（SSTR）的标准方法。它通常用于胃肠胰腺神经内分泌肿瘤（GEP-NET）分期，并且代表用生长抑素（SST）类似物治疗的选择标准。据报道，免疫组织化学（IHC）是一种检测SSTR的可靠方法，其灵敏度在理论上优于SRS。方法和研究设计。我们回顾性分析了1997年至2007年间在本研究所就诊的连续GEP-NET患者队列中IHC在检测SSTR中的敏感性和特异性。IHC分析仅限于SSTR2和SSTR5，并且根据两种不同的解释结果计分系统。 SRS被用作黄金标准。结果。入选了44例患者。 24例（55％）患有前肠类癌，9例（20％）中肠类癌，2例（5％）后肠类癌以及9例（20％）患有原发灶未知的GEP-NET。无论采用哪种IHC评分系统，IHC和SRS之间的一致性都很高（73％和70％）。根据所使用的评分系统，IHC的敏感性分别为89.3％和78.6％，特异性为43.8％和50％。结论。尽管显示SSTR2由IHC在多达50％的SRS看不到的肿瘤中表达，但SRS仍然是GEP-NETs诊断和治疗管理中的首选方法。需要更多的病理学和临床数据，以正确了解在SRS不吸收肿瘤的情况下，免疫组织化学检测SSTR表达的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号